J&J revenue misses on lower-than-expected pharmaceutical sales

J&J revenue misses on lower-than-expected pharmaceutical sales Johnson & Johnson, which is in the process of completing its $30 billion acquisition of Swiss biotech Actelion, reported on Tuesday quarterly revenue that missed analysts' estimates, hurt by lower demand for its pharmaceutical products. The diversified healthcare company's sales rose to $17.77 […]